Randomized, placebo-controlled, dose-ranging clinical trial of intravenous microplasmin in patients with acute ischemic stroke

Stroke

Volumn 40, Issue 12, 2009, Pages 3789-3795

  Thijs, Vincent N S ^a,b   Peeters, Andre ^c   Vosko, Milan ^d   Aichner, Franz ^d   Schellinger, Peter D ^e   Schneider, Dietmar ^f   Neumann Haefelin, Tobias ^g   Röther, Joachim ^h   Davalos, Antoni ⁱ   Wahlgren, Nils ^j   Verhamme, Peter ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c Hôpital Saint Luc   (Belgium)

^d KEPLER UNIVERSITY HOSPITAL   (Austria)

^e UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^f UNIVERSITY OF LEIPZIG   (Germany)

^g GOETHE UNIVERSITY   (Germany)

^h KLINIKUM MINDEN   (Germany)

ⁱ HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^j KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Acute care; Acute stroke; Antithrombotics; Brain imaging; Brain infarction; Diffusion weighted imaging; Thrombolysis; Thrombolytic Rx

Indexed keywords

ALPHA 2 ANTIPLASMIN; GELATINASE A; GELATINASE B; MICROPLASMIN; PLACEBO; PLASMIN; PLASMINOGEN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME BLOOD LEVEL; FEMALE; HEMODYNAMIC PARAMETERS; HEMODYNAMICS; HUMAN; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECANALIZATION; REPERFUSION; SYMPTOM;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CEREBRAL REVASCULARIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRINOLYSIN; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PLACEBOS; STROKE; TREATMENT OUTCOME;

EID: 73449143461     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.560201     Document Type: Article

References (15)

1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333:1581-1587.
2. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
3. Nagai N, Demarsin E, Van Hoef B, Wouters S, Cingolani D, Laroche Y, Collen D. Recombinant human microplasmin: production and potential therapeutic properties. J Thromb Haemost. 2003;1:307-313.
4. Nagai N, De Mol M, Van Hoef B, Verstreken M, Collen D. Depletion of circulating alpha(2)-antiplasmin by intravenous plasmin or immunoneu-tralization reduces focal cerebral ischemic injury in the absence of arterial recanalization. Blood. 2001;97:3086-3092.
5. Suzuki Y, Chen F, Ni Y, Marchal G, Collen D, Nagai N. Microplasmin reduces ischemic brain damage and improves neurological function in a rat stroke model monitored with MRI. Stroke. 2004;35:2402-2406.
6. Nagai N, De Mol M, Lijnen HR, Carmeliet P, Collen D. Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. Circulation. 1999;99:2440-2444.
7. Lapchak PA, Araujo DM, Pakola S, Song D, Wei J, Zivin JA. Micro-plasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits. Stroke. 2002;33:2279-2284.
8. Rasmussen RS, Overgaard K, Pakola S, Boysen G. Effects of microplasmin on recovery in a rat embolic stroke model. Neurol Res. 2008;30:75-81.
9. Pakola S, Cahillane C, Stassen J, Lijnen H, Verhamme P. Neutralization of alfa 2-antiplasmin by microplasmin: a randomized, double-blind, placebo-controlled, ascending-dose study in healthy male volunteers. Clin Therap. 2009;31:1688-1706.
10. Albers GW, Thijs VN, Wechsler L, Kemp S, Schlaug G, Skalabrin E, Bammer R, Kakuda W, Lansberg MG, Shuaib A, Coplin W, Hamilton S, Moseley M, Marks MP. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol. 2006;60:508-517.
11. Sherman DG, Atkinson RP, Chippendale T, Levin KA, Ng K, Futrell N, Hsu CY, Levy DE. Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial. JAMA. 2000;283:2395-2403.
12. Hennerici MG, Kay R, Bogousslavsky J, Lenzi GL, Verstraete M, Orgogozo JM. Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial. Lancet. 2006;368:1871-1878.
13. Kelly MA, Shuaib A, Todd KG. Matrix metalloproteinase activation and blood-brain barrier breakdown following thrombolysis. Exp Neurol. 2006;200:38-49.
14. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, Quintana M, Alvarez-Sabin J. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003;107:598-603.
15. Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke. 2007;38:967-973.